Fountain Healthcare Partners Research
Investment Thesis
Fountain Healthcare Partners is a life sciences venture fund that provides risk capital and expertise to entrepreneurs building life sciences companies. The firm describes its approach as focus: more than 30 years of investment experience, a narrow set of sectors, and a defined exit horizon. The tagline on its site is "Capital today, success tomorrow, healthcare advanced." The partners come largely from Elan Corporation's business development and corporate venture groups, and they pair scientific training (PhD chemist, pharmacist, PhD biochemists, medical scientist) with deal and finance backgrounds.
Sector Focus
The stated sectors are specialty pharma, biopharmaceuticals, medical devices, and diagnostics. The portfolio is weighted to immunology and inflammation (Inotrem, Madeleine, Calypso, Inflazome, Priothera), neuroscience (Exciva, Syndesi, Altay, Neuromod), cardiovascular (XyloCor, Corteria, Vivasure, Neuravi), and surgical or interventional devices (Medical Microinstruments, Neurent, Mainstay). Justin Lynch leads the medical device deals; Ena Prosser invests across all sectors.
Stage Focus
The firm states a focus on seed and early stage. In practice it follows companies into later rounds: it appears in Exciva's Series B, Neurent's Series C, and MMI's Series D.
Check Size
The site does not state a check size. The firm manages more than 425 million euros across four funds, so check size is not inferred here.
Lead Tendency
The firm says it will lead or co-lead an investment syndicate. Lead tendency is recorded as both.
Recent Activity
Fund 4 is the current fund, with Exciva, Madeleine Therapeutics, and Altay Therapeutics as listed companies. Recent announcements on the news page:
- October 2026: Altay Therapeutics closed a $37M Series A for the first oral DUX4 inhibitor for FSHD.
- October 2026: MMI raised $125M in a Series D for the Symani Surgical System.
- February 2026: Neurent Medical raised 62.5M euros in an oversubscribed Series C.
- January 2026: Exciva raised 51M euros ($59M) in a Series B, later extended.
- January 2026: Haemonetics acquired Vivasure Medical for up to 185M euros.
Portfolio Highlights
Exits include Amarin (Vascepa), Civitas (acquired by Acorda for $525M in 2014), Genable (Spark, 2016), Neuravi (J&J, 2017), Innocoll (Gurnet Point, 2017), Inflazome (Roche, 2020, 380M euros upfront), KaNDy (Bayer, 2020, $425M upfront; its drug Lynkuet is now approved in the US and EU), Syndesi (AbbVie, 2022, $130M upfront), Calypso (Novartis, 2024, up to $425M), and Vivasure (Haemonetics, 2026). Mainstay Medical went public in 2014. Several companies ceased operations, including Trino, Palyon, Opsona, Chrono, Velicept, Ermium, and Dualyx.
Team
- Manus Rogan: Managing Partner and co-founder, PhD chemist, ex-GSK and Elan, leads investor relations and fundraising, sits on the boards of Priothera and Neuromod
- Aidan King: Managing Partner and co-founder, pharmacist, ex-Elan and Bio-IB, focuses on US investments, sits on the boards of XyloCor, Corteria, and Ermium
- Ruthanne Monaghan: Partner and CFO, joined 2020, ex-Hostelworld and Trinity Venture Capital
- Ena Prosser: Partner, ex-Enterprise Ireland and Elan, led the NeRRe and Inotrem investments
- Justin Lynch: Partner, medical device specialist, led Vivasure, MMI, and Neurent
- Tania Papkovskaia: Principal, joined 2019, ex-Gerson Lehrman Group
- Chris Tapper: Senior Associate, ex-Cambridge Innovation Capital
- Annie Flynn: Financial Controller, joined 2024
Decision Process
The firm operates as a partnership with several co-founding managing partners. The site gives no detail on committee structure or timeline.
Founder Preferences
The site says it invests in people as much as science and wants to hear from founders building breakthrough therapies or medical technologies. Its portfolio shows a pattern of backing European spin-outs from large pharma (Merck Serono, Sanofi) and academic science.
Geographic Focus
Europe and the United States. Offices are in Dublin (IFSC) and New York (115 Broadway). Portfolio companies are based in Ireland, the UK, France, Belgium, Italy, the Netherlands, and the US.